New-onset dermatomyositis following COVID-19: A case report
Authors: Hiroshi Shimizu, Haruki Matsumoto, Tomomi Sasajima, Tomohiro Suzuki, Yoshinori Okubo, Yuya Fujita, Jumpei Temmoku, Shuhei Yoshida, Tomoyuki Asano, Hiromasa Ohira, Yutaka Ejiri, Kiyoshi Migita
Journal: Front Immunol (2022)
Keywords: covid-19, anti-aminoacyl trna synthetase (ars) antibodies, anti-synthetase antibodies, autoimmune diseases, dermatomyositis
MeSH terms: Autoimmune Diseases / complications, COVID-19 / complications, Dermatomyositis / complications, Dermatomyositis / diagnosis, Dermatomyositis / drug therapy, Exanthema, Lung Diseases, Interstitial / diagnosis, Lung Diseases, Interstitial / drug therapy, Lung Diseases, Interstitial / etiology, Myositis, Case Reports, Autoantibodies, Humans, Male, Middle Aged, SARS-CoV-2, Autoantibodies

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the infected individuals have recovered without complications, but a few patients develop multiple organ involvements. Previous reports suggest an association between COVID-19 and various inflammatory myopathies, in addition to autoimmune diseases. COVID-19 has been known to exacerbate preexisting autoimmune diseases and trigger various autoantibodies and autoimmune disease occurrence. Here we report a case of complicated COVID-19 with anti-synthetase autoantibodies (ASSs) presenting with skin rash, muscle weakness, and interstitial lung disease (ILD) and subsequently diagnosed with dermatomyositis (DM). A 47-year-old Japanese male patient without any previous history of illness, including autoimmune diseases, presented with a high fever, sore throat, and cough. Oropharyngeal swab for SARS-Cov-2 polymerase chain reaction tested positive. He was isolated at home and did not require hospitalization. However, his respiratory symptoms continued, and he was treated with prednisolone (20 mg/day) for 14 days due to the newly developing interstitial shadows over the lower lobes of both lungs. These pulmonary manifestations remitted within a week. He presented with face edema and myalgia 4 weeks later when he was off corticosteroids. Subsequently, he presented with face erythema, V-neck skin rash, low-grade fever, and exertional dyspnea. High-resolution computed tomography of the chest showed ILD. Biochemical analysis revealed creatine kinase and aldolase elevations, in addition to transaminases. Anti-aminoacyl tRNA synthetase (ARS) was detected using an enzyme-linked immunosorbent assay (170.9 U/mL) (MESACUP™ (Medical & Biological Laboratories, Japan), and the tRNA component was identified as anti-PL-7 and anti-Ro-52 antibodies using an immunoblot assay [EUROLINE Myositis Antigens Profile 3 (IgG), Euroimmun, Lübeck,Germany]. The patient was diagnosed with DM, especially anti- synthase antibody syndrome based on the presence of myositis-specific antibodies, clinical features, and pathological findings. The present case suggests that COVID-19 may have contributed to the production of anti-synthetase antibodies (ASAs) and the development of de novo DM. Our case highlights the importance of the assessment of patients who present with inflammatory myopathy post-COVID-19 and appropriate diagnostic work-up, including ASAs, against the clinical features that mimic DM after post-COVID-19.